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Background: The duration of immunity against severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) is still uncertain, but 
it is of key clinical and epidemiological importance. Seasonal human 
coronaviruses (HCoV) have been circulating for longer and, therefore, 
may offer insights into the long-term dynamics of reinfection for such 
viruses. 
Methods: Combining historical seroprevalence data from five studies 
covering the four circulating HCoVs with an age-structured reverse 
catalytic model, we estimated the likely duration of seropositivity 
following seroconversion. 
Results: We estimated that antibody persistence lasted between 0.9 
(95% Credible interval: 0.6 - 1.6) and 3.8 (95% CrI: 2.0 - 7.4) years. 
Furthermore, we found the force of infection in older children and 
adults (those over 8.5 [95% CrI: 7.5 - 9.9] years) to be higher compared 
with young children in the majority of studies. 
Conclusions: These estimates of endemic HCoV dynamics could 
provide an indication of the future long-term infection and reinfection 
patterns of SARS-CoV-2.
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Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
a novel beta coronavirus, was first detected in December 
2019 and has since spread globally causing high morbidity 
and mortality. There is evidence of some short-term sterilising 
immunity (protection against reinfection and symptoms) fol-
lowing infection with SARS-CoV-21, but also some reports of 
reinfection2. However, there is currently limited evidence on 
the duration of immunity conferred by SARS-CoV-2 infection. 
Given the limited duration of SARS-CoV-2 circulation to date, 
the dynamics of antibody responses of seasonal human coro-
naviruses (HCoV) could provide insights into the possible 
long-term potential for reinfections3. The duration of immu-
nity following infection is of both clinical and epidemiological 
importance, as it provides information as to how long previ-
ously infected individuals may no longer be at risk of infection 
and disease, as well as influencing the long-term dynamics of 
epidemics4 and enabling the interpretation of population-wide 
serological data5.
There are four circulating HCoVs: HCoV-NL63 and HCoV-
229E (alpha coronaviruses), HCoV-OC43 and HCoV-HKU1 
(beta coronaviruses). HCoV-OC43 and HCoV-229E were first 
identified in the 1960s, but HCoV-NL63 and HCov-HKU1 
were not identified until 2004 and 2005 respectively6,7. Like 
SARS-CoV-2, these typically cause respiratory tract infections. 
A small number of human challenge studies have looked at 
the duration of immunity to these viruses. Callow et al.8 found 
that six out of nine participants were reinfected when chal-
lenged with HCoV-229E again one year later, as measured by a 
rise in IgG antibodies and viral shedding. However, the period of 
viral shedding was shorter following the second inocula-
tion, and none of the participants developed symptoms. Reed9 
found that reinfection did not occur when participants were 
re-inoculated with a homologous strain approximately one 
year following infection, but participants had partial immunity 
against reinfection with a heterologous strain. Taken together 
these results suggest that immunity against infection with a 
homologous strain could last at least one year8,9.
There are also a small number of cohort and community- 
based surveillance studies which have looked at reinfection 
of seasonal HCoV. One study looked at HCoV reinfection in 
a small cohort of ten individuals over 35 years and found the 
median reinfection times to be 30 months, but with reinfec-
tion often occurring at 12 months10. A larger study looking at 
data from Flu Watch, a community cohort study which measures 
the incidence and transmission of respiratory viruses, found that 
between 2006 and 2011, eight subjects were reinfected with 
a seasonal HCoV (of 216 with confirmed first infection), and 
the time between reinfection ranged from 7 to 56 weeks. None 
of these reinfections were with the same strain, providing 
some evidence of lasting immunity11. However, a community 
surveillance study conducted in Kenya in 2010 over six 
months found evidence of high numbers of repeat infections of 
HCoV-NL63 (20.9%), HCoV-OC43 (5.7%), and HCoV-229E 
(4.0%). The majority of these reinfections showed reduced 
virus replication in the second infection, and a lower proportion 
of individuals had symptoms following the second infection12. 
Furthermore, another study conducted in New York City found 
that reinfections with the same strain can occur within one 
year13. Care should be taken with the interpretation of these stud-
ies since we do not know the background exposure rates, and 
this will influence the estimates of duration of immunity.
If infections are fully immunising – as is the case for pathogens 
like measles, pertussis and varicella zoster – then seroprevalence 
would be expected to accumulate over time14, and hence with 
age, with little waning of responses. The dynamics can therefore 
be captured with catalytic models of seroconversion15, which 
enables estimation of the force of infection (FOI, the rate at 
which susceptible individuals acquire infection and seroconvert). 
In contrast, when individuals serorevert, i.e. their immunity 
wanes by the progressive loss of protective antibodies against a 
disease over time, ‘reverse catalytic models’ can jointly estimate 
FOI and waning of immunity16. Variation in FOI with age may 
further complicate the dynamics, particularly if a high infec-
tion rate in children is followed by a lower rate in adults as 
well as waning of seroprevalence. To understand how serocon-
version, waning and age-variation in infection risk could shape 
population-level seroprevalence, we combine age-stratified 
data with age-structured reverse catalytic models, and estimate 
the likely duration of seropositivity following seroconversion 
for the four seasonal coronaviruses.
Methods
Human seroprevalence from four different human coronavi-
rus strains (229E, HKU1, NL63, and OC43) were identified in a 
recent systematic review7. Studies which did not include esti-
mates for individuals under 10 years old17 were excluded, as well 
as studies with a small number of data points18. A total of six 
different studies were included, covering the four seasonal 
HCoVs, with some studies reporting on multiple strains19–24. 
Two studies were reported separately for two different strains, 
but the overall study population was the same21,22. A summary 
of these studies is presented in Table 1. The different assays 
used in each study for the different strains is shown, and where 
the antibody detected was specified this is included in the table. 
To account for maternal immunity individuals aged ≤1 year were 
excluded. The full dataset used for this analysis can be found 
as underlying data25.
To explore the duration of antibody persistence for different 
seasonal coronaviruses, where detectable antibodies is defined 
as seropositivity, we developed age-structured reverse cata-
lytic models. The basic reverse catalytic model follows 
individuals from birth and assumes that there is a constant 
FOI (λ), which is independent of age (a) and calendar year, and 
that immunity (as measured by serological status) wanes over 
time, at a rate ω. This model also assumes that the mortal-
ity rate for susceptible and infectious individuals is the same. 
The expression for the proportion of individuals age a who are 
seropositive, z(a), in the reverse catalytic model is as follows:




where λ is the FOI, ω is immunity waning rate and a is age.
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We then extended the reverse catalytic model to allow for a dif-
ferent FOI by age. The expressions for seroprevalence in 
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Where z(a) is those who are seropositive at age a, λ1 is the 
FOI in young age groups, λ2 is FOI in the old age group, ω is 
waning, a is age, a
0
 is the age cut-off used to define the young 
and old group, and the relative change in FOI, α, is the change 
in FOI in the older age group. In our analysis, we allowed λ
1
 to 
vary by study and strain, to account for local differences in 
population-level transmission dynamics, while the average rate 
of waning within a given individual was assumed to be universal 
and was jointly estimated across all studies and strains. This 
means that one overall estimate of waning was obtained. Some 
of the studies occurred in the same setting, and so the under-
lying contact patterns were presumed to be the same (in total 
we identified five settings). Therefore, the relative change in 
FOI (α) and the age at cut-off (a
0
) were jointly estimated across 
settings. This model assumes no cross-protection between 
strains. Annual attack rates were calculated after estimating the 
FOI using the following expression,
1 .Attack rate e λ−= −  
To reflect uncertainty in current knowledge about the transmis-
sion dynamics of HCoVs, weakly informative distributions were 
chosen as priors for ω, the rate of waning over time, and a
0
, 
the age at the cut-off time. Specifically, uniform priors from 0 
to 5 and 0 to 20 years, respectively, were chosen as we were 
interested in the change in FOI in children and young adults. 
For FOI, a Gamma distribution, parameterised using plausible 
attack rates of HCoV, with a mean of 0.3 (corresponding to an 
attack rate of 26%) was chosen (shape = 1.2 and scale = 0.25). 
There is little information on the attack rate of HCoVs, but 
there have been several systematic reviews and meta-analy-
ses looking at unvaccinated individuals which have reported 
the attack rate to range between 15.2% – 22.5% in children and 
3.5% – 10.7% in adults26–28. Modelling studies using serological 
influenza data predicted estimates from 20 – 60%29,30. We expect 
the attack rate for HCoV may be lower based on the epidemiol-
ogy of these viruses in children31, but we selected a prior which 
covers a range of plausible values. For the relative change in 
FOI (α) we did not have any prior information. Therefore, we 
selected a prior with median 1, which presumes no difference 
between FOI in young compared with FOI in old and allowed 
for a range of plausible values using a gamma distribution 
(shape = 5, scale = 0.2).
Several sensitivity analyses were conducted to assess the 
robustness of these results. Firstly, the choice of priors for the 
FOI was explored, and a less informed prior was tested (FOI ~ 
Normal (mean 0.3, standard deviation 0.5)). Secondly, wan-
ing was estimated by strain, instead of being jointly fitted across 
all studies. Thirdly, the relative change in FOI (α) and age at 
cut-off (a
0
) were held across all studies (instead of allowing 
them to vary by setting) to explore the impact on the estimate 
for waning. The impact of excluding the youngest age groups 
(≤1 year) was also explored, and a model was run which included 
individuals ≤1 year. Finally, the primary model (age-varying 
Table 1. Characteristics of studies used to fit the model.
Strain Author (year 
published)







HCoV-HKU1 Chan (2009) 19342289 709 Hong Kong Not specified ELISA (IgG)
Zhou (2013)a 24040960 789 China 1999 – 2011 IFA (IgG)
HCoV-OC43 Zhou (2013)a 24040960 789 China 1999 – 2011 IFA (IgG)
Monto (1974)c 4816305 910 USA 1965 – 1969 CF or HAI
Sarateanu (1980) 6248465 3,016 Germany 1974 – 1976 HI
HCoV-NL63 Shao (2007)b 17889596 243 USA 2003 – 2004 ELISA (IgG)
Zhou (2013)a 24040960 789 China 1999 – 2011 IFA (IgG)
HCoV-229E Shao (2007)b 17889596 243 USA 2003 – 2004 ELISA (IgG)
Zhou (2013)a 24040960 789 China 1999 – 2011 IFA (IgG)
Cavallaro (1970)c 5504709 307 USA 1965 Neutralization
Enzyme-linked immunosorbent assays (ELISA), immunofluorescence assays (IFA), western blots, complement fixation (CF), 
hemagglutination inhibition assays (HAI). Studies which occurred in the same setting are denoted by the superscripts, a, b 
and c.
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FOI model) was fitted using only half the data (seropreva-
lence studies from two strains), to explore whether the results 
from one study was heavily influencing the results. For this 
model, waning, the relative change in FOI (α) and age at cut-off 
(a
0
) were held across all studies. A description of these models 
is presented in Table 2.
Bayesian inference was used to fit the sero-catalytic models 
to the seroprevalence data, using Markov chain Monte Carlo 
(MCMC) with the Gibbs sampling algorithm to estimate model 
parameters. To do so, we used the following binomial likelihood 
representing seropositivity by age (a), study (i) and strain (j)
~ ( , ),ija ija ijay Binomial P N
where N
ija
 is total number of individuals by age group, strain 
and study, and P
ija
 is the proportion of individuals who 
are seropositive. The inference was impleented in RJags 
(version 4–10)32. The Gelman-Rubin statistic was used to evalu-
ate MCMC convergence, and a threshold of <1.1 was cho-
sen. The effective sample size (ESS), which is the estimated 
number of independent samples accounting for autocorrela-
tions generated by the MCMC run, was checked, and an ESS 
>200 was used. All analysis and calculations were performed 
using R version 3.6.1. Model selection was based on the low-
est value of the deviance information criterion (DIC). All 
code is available here at GitHub25.
Results
Using a reverse catalytic model, which allowed the FOI to 
change in individuals by age, we estimated the duration of 
antibody persistence for the four seasonal HCoVs25. Despite hav-
ing only four parameters by study, our model could capture the 
overall trends in most studies (Figure 1). Waning was jointly 
fitted across all studies and strains to obtain one overall esti-
mate, and the duration of antibody persistence was estimated 
to be 3.75 (95% credible interval [CrI]: 1.96 - 7.38) years 
(Table 3). The FOI across all studies and strains in the young 
age group ranged from 0.02 (95% CrI: 0.01 - 0.05) to 1.06 
(95% CrI: 0.57 - 1.68). The cut-off (age at which the FOI 
changes) ranged between 2.35 (95% CrI: 0.31 - 17.51) to 16.58 
(95% CrI: 7.71 - 19.81) years. The relative change in FOI 
(Alpha) which measures the relative value of FOI in the young 
age group compared with the older age group ranged from 
0.72 (95% CrI: 0.3 - 1.17) to 2.48 (95% CrI: 1.96 - 2.99). 
For three of the study settings, the FOI in the older age group 
was higher (Figure 2). A sensitivity analysis was conducted 
using less informative priors for the FOI parameters, where a 
Table 2. Description of models explored.
Model Priors Number of 
parameters
Main model: 
Reverse catalytic model with 
age-varying FOI (alpha and cut-off varying across settings) 
- More informed priors
FOI ~ gamma(shape = 1.2, scale = 0.25) 
Waning ~ uniform(0,5) 
Alpha ~ gamma(shape = 5, scale = 0.2) 
Cut-off ~ uniform(0,20)
21
Reverse catalytic model with 
age-varying FOI (alpha and cut-off varying across settings) 
- less informed priors
FOI ~ normal(0.3,0.5) 
Waning ~ uniform(0,5) 
Alpha ~ gamma(shape = 5, scale = 0.2) 
Cut-off ~ uniform(0,20)
21
Reverse catalytic model with 
age-varying FOI (alpha and cut-off varying across settings, 
waning varying by strain) 
FOI ~ gamma(shape = 1.2, scale = 0.25) 
Waning ~ uniform(0,5) 
Alpha ~ gamma(shape = 5, scale = 0.2) 
Cut-off ~ uniform(0,20)
24
Reverse catalytic model with 
age-varying FOI (alpha and cut-off held across settings)
FOI ~ gamma(shape = 1.2, scale = 0.25) 
Waning ~ uniform(0,5) 
Alpha ~ gamma(shape = 5, scale = 0.2) 
Cut-off ~ uniform(0,20)
13
Reverse catalytic model with 
age-varying FOI (alpha and cut-off varying across settings) 
using all data
FOI ~ gamma(shape = 1.2, scale = 0.25) 
Waning ~ uniform(0,5) 
Alpha ~ gamma(shape = 5, scale = 0.2) 
Cut-off ~ uniform(0,20)
21
Reverse catalytic model FOI ~ gamma(shape = 1.2, scale = 0.25) 
Waning ~ uniform(0,5)
11
Alpha (α), the relative change in FOI; Cut-off (a0), the age at cut-off.
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normal distribution was used (extended data Figure 1, 
Table 133). This model estimated a shorter duration of anti-
body persistence [0.93 (95% CrI: 0.60 - 1.64) years]. The FOI 
across all studies and strains were higher, ranging from 0.09 
(95% CrI: 0.04 - 0.16) to 3.22 (95% CrI: 1.95 - 4.85), with six 
studies reporting FOI estimates > one, which is equivalent to 
an attack rate of >63%. The relative change in FOI and cut-
off were similar for both models. This model had a lower DIC 
(476.8 compared with 480.8; Table 4), with a DIC differ-
ence of 4, however, the high FOI estimates indicate that this 
model may be less plausible. As an additional sensitivity we 
allowed the waning estimate to vary by strain (extended data 
Table 233). This model estimated the duration of immunity to be 
similar for all strains, ranging from 2.26 (1.06 – 5.07) years for 
HCoV-OC43 to 4.09 (1.91 – 9.60) years for HCoV-229E.
When the relative change in FOI and cut-off parameters were 
simultaneously estimated by setting (extended data Figure 2, 
Table 333) the duration of antibody persistence was estimated 
to be shorter, 2.20 (95% CrI: 1.57 - 3.08) years, although the 
confidence intervals overlap with the main model. The FOI 
ranged from 0.04 (95% CrI: 0.03 - 0.06) to 0.88 (95% CrI: 0.67 
- 1.19). The overall model DIC was higher (548.2 compared 
with 480.8; Table 4), indicating that this model did not have 
as much support.
We also tested a basic reverse catalytic model, where the 
FOI was not allowed to vary by age, and this model estimated 
a longer duration of antibody persistence (7.69 [95% CrI: 
6.25 - 9.09] years; extended data Table 4, Figure 333). The DIC 
value for the basic reverse catalytic model was higher, (608.3 
Figure 1. Reverse catalytic model with age-varying FOI. The points are the observed proportion of seropositive individuals from each 
study (with confidence intervals), i.e. the data that was fit to. The lines are the seroprevalence curves, sampled from the fitted model, where 
the shaded region represents the 95% credible interval of the predictive posterior distribution. FOI was allowed to vary by study, whilst the 
relative change in FOI (Alpha) and cut-off were allowed to vary by setting. Waning was jointly fit across all studies and strains.
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Table 3. Parameter estimates from the age-varying FOI reverse catalytic model (median [95% CrI]). 
FOI was allowed to vary across study, while waning was simultaneously estimated across all studies. The relative 
change in FOI (Alpha) and the cut-off were allowed to vary across study settings.
Strain First Author FOI Relative change 
in FOI (Alpha)
Cut-off Waning
HCoV-229E Shao 1.06 (0.57 – 1.68) 0.78 (0.35 – 1.68) 9.5 (0.59 – 19.47)
0.27 (0.14 - 0.51)
Zhou 0.11 (0.06 – 0.3) 1.57 (0.8 – 2.65) 2.35 (0.31 – 17.51)
Cavallaro 0.02 (0.01 - 0.05) 0.72 (0.3 - 1.17) 9.14 (0.57 - 19.28)
HCoV-HKU1 Chan 0.59 (0.32 – 0.89) 2.27 (1.44 – 3.45) 16.58 (7.71 – 19.81)
Zhou 0.64 (0.35 – 0.96) 1.57 (0.8 – 2.65) 2.35 (0.31 – 17.51)
HCoV-OC43 Zhou 0.07 (0.04 – 0.19) 1.57 (0.8 – 2.65) 2.35 (0.31 – 17.51)
Monto 0.19 (0.11 – 0.35) 0.72 (0.3 – 1.17) 9.14 (0.57 – 19.28)
Sarateanu 0.5 (0.27 – 0.74) 2.48 (1.96 – 2.99) 9.93 (7.34 – 14.84)
HCoV-NL63 Zhou 0.41 (0.26 – 0.67) 1.57 (0.8 – 2.65) 2.35 (0.31 – 17.51)
Shao 1.06 (0.57 – 1.68) 0.78 (0.35 – 1.68) 9.5 (0.59 – 19.47)
Figure 2. Posterior estimates for the relative change in FOI (alpha) from the age-varying reverse catalytic model for each 
study setting. The alpha estimate from the model where alpha and cut-off were simultaneously estimated across studies is shown 
in grey as “combined”. The prior is shown as a dashed line.
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Figure 3. (A) Proportion of individuals age 30 who are seropositive for different estimates of force of infection (FOI). The catalytic model is 
shown in red, the reverse catalytic model in green, and the reverse catalytic model with time-varying FOI is shown in blue. Model estimates 
were used for the parameter values (relative change in FOI (alpha),1.93 [1.69 – 2.19]; waning, 0.45 [0.32 – 0.64]; cut-off, 8.49 [7.52 – 9.94]). 
(B) Estimated proportion of individuals experiencing infections by age, using the pooled median estimate across studies for FOI (0.46), and 
median estimates for waning (0.45), alpha (1.93) and cut-off (8.49).
compared with 480.8) indicating that this basic model did not 
have strong support among the models considered (Table 4).
To explore the effect of excluding the youngest ages (≤1 year), 
a sensitivity analysis was done where these individuals were 
included within the analysis. The duration of antibody persist-
ence was found to be slightly shorter (2.04 [95% CrI: 0.1.28 
-1.4.76] years) and the FOI was found to be higher for all stud-
ies, ranging from 0.04 (95% CrI: 0.02 - 0.07) to 2.92 (95% 
CrI: 2.08 - 4.01); extended data Table 5, Figure 433). The esti-
mates for the relative change in FOI were found to be very 
similar to the model which excluded this age group.
As an additional sensitivity analysis, we refit the models using 
data for only two strains at a time, and estimated the FOI, 
waning and the relative change in FOI (extended data Table 633). 
We found that although the results varied, the overall trends 
were the same, indicating that the model did not rely heavily on 
one dataset. The waning estimates varied from 1.80 years (95% 
CrI: 1.17 - 2.67) to 5.26 years (95% CrI: 2.53 - 13.56).
Using the parameters for the relative change in FOI and 
waning estimated from the age-varying reverse catalytic model 
where the relative change in FOI and the age at cut-off were 
simultaneously estimated across settings, we simulated the pro-
portion of individuals aged 30 years that would be seropositive 
using a range of FOI estimates to show how the proportion 
changes using the different models (Figure 3A). We also 
used the pooled estimate across all studies of FOI to estimate 
the proportion exposed at a given age to provide an indica-
tion of how many infections we might expect to see by age 
(Figure 3B).
Table 4. Comparison of duration of antibody persistence estimates from the different models explored.
Model Reverse catalytic model with 
age-varying FOI (alpha 
and cut-off varying across 
settings) - More informed 
priors
Reverse catalytic model 
with 
age-varying FOI (alpha 
and cut-off varying across 









Duration of antibody 
persistence (years)
3.75 (1.96 – 7.38) 0.93 (0.60 – 1.64) 2.20 (1.57 – 3.08) 7.69 (6.25 – 9.09)
DIC 480.8 476.8 548.2 608.3
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Discussion
To date, there has been limited evidence about the duration 
of immunity to SARS-CoV-2. Given the inevitable right 
censoring of data during an emerging infectious disease pan-
demic, understanding the duration of protection following 
infection with HCoV could help provide insights which will 
be relevant to SARS-CoV-2. Using an age-varying reverse 
catalytic model, we estimated the overall duration of immu-
nity, as measured by seropositivity, to be between 0.9 (95% 
CrI: 0.6 - 1.6) years and 3.8 (95% CrI: 2.0 - 7.4) years for 
HCoV’s. When waning was estimated by strain, we found com-
parable estimates of the duration of seropositivity, indicating that 
the assumption that waning is similar across strains holds true. 
Previous studies have produced varied estimates for the dura-
tion of immunity for HCoVs. One study estimated the median 
duration of immunity to be 2.5 years10, and Reed found 
immunity lasts at least one year9. However, several studies 
have reported reinfection occurring in less than one year8,11–13. 
Aldridge et al.11 found that reinfection with HCoV did not 
occur with the same strain, but Kiyuka et al.12 found reinfec-
tion frequently occurred with the same strain within a six 
month period. The reverse catalytic model assumes that waning 
occurs at a constant rate, however, individuals may become 
reinfected within a shorter time period than average, and 
conversely some will take longer. Some evidence also exists 
for the duration of immunity to SARS-CoV-2. A recent 
survey of health care workers in Oxford, UK, found that pro-
tection against reinfection with SARS-CoV-2 lasts at least six 
months34, whilst another study of health care workers from 
across the UK conducted by Public Health England found that 
immunity lasts for at least five months2. This seems to align 
with what is known about reinfection in seasonal HCoVs. 
However, these studies only followed up individuals for six 
months and five months respectively, and longer follow-up 
times are needed. Future studies could also work to untangle the 
relationship between seroreversion as a result of waning homo-
typic antibody responses and antigenic evolution leading to a 
mismatch between prior immunity and circulating viruses33.
More informed priors for the FOI based on attack rates for 
influenza, resulted in higher estimates for the duration of 
seropositivity. When we used less informed priors for the FOI, 
a lower estimate of duration of seropositivity was obtained. 
However, this model produced higher estimates of FOI, with 
six studies reported FOI estimates in the young age group 
greater than one (attack rate >63%). There is limited infor-
mation on the attack rate of seasonal HCoV, however there 
have been numerous studies looking at influenza. Previous 
systematic reviews have estimated the attack rate of influenza 
to be between 3.5% and 22.5%26–28, whilst modelling stud-
ies have estimated this to be higher, 20 – 60%29,30. Based on 
reporting rates of seasonal HCoV we would expect the 
attack rate to be lower than influenza. Therefore, this suggests 
that the results from the model with less informative priors are 
less plausible. Maternally derived immunity may also have a 
role, protecting young infants from infection. We tested this 
with a model which included individuals ≤1 year. This resulted 
in a shorter estimate of the duration of antibody persistence, 
and a higher FOI, suggesting that maternal immunity may 
be important.
A wide range of different assays were used in the stud-
ies we considered in our analysis, including enzyme-linked 
immunosorbent assays (ELISA), immunofluorescence assays 
(IFA), western blots, and complement fixation (CF), hemag-
glutination inhibition assays (HAI) and neutralisation assays. 
Neutralisation assays are considered to be the gold standard 
as they measure the ability of the sera to inhibit viral 
processes36. Only Cavallaro and Monto22 used a neutralisation 
assay. Other assays, such as ELISA and IFA, do not assess the 
functionality of the antigen, but instead detect the presence of 
antibodies in a sample. Zhou et al.19 and Chan et al.23 used IFA 
to detect levels of IgG antibodies. A recent study provided 
evidence that IgG antibodies in SARS-CoV-2 are correlated 
with neutralising antibodies, and may therefore act as a 
correlate of sterilising immunity37, whilst another study suggested 
that neutralizing antibodies may be correlated with protection 
against reinfection1. Therefore, although antibody prevalence 
does not equate to immunity for seasonal HCoVs, prevalence 
of IgG antibody may be a good correlate of immunity. How-
ever, all of these assays only assess humoural immunity, and it is 
thought that cellular immunity also has a role SARS-CoV-2, and 
so it is likely to be also important in seasonal HCoVs38–40.
The seroprevalence surveys included in this study were 
conducted in different countries and settings (USA, China, 
Germany and Hong Kong), as well as in different time-periods 
(ranging from 1965–2011). It is likely that there are differences 
in social structure and contact patterns between these settings. 
Furthermore, individual level data was not available for these 
studies, and instead aggregated data was used. Finer resolu-
tion, particularly for the younger age groups, would have 
helped to provide more certainty with these estimates. In 
addition, we did not take into consideration cross protec-
tion between seasonal coronavirus strains. There is also some 
evidence that there is cross-reactivity with different coronavi-
ruses, which may lead to false positive results. A recent sys-
tematic review found that there was some cross-reactivity that 
occurred within alpha (HCoV-229E and HCoV-NL63) and 
beta (HCoV-OC43 and HCoV-HKU1) coronaviruses, but 
minimal reactivity between alpha and beta coronaviruses7. 
However, it is not clear whether cross-reactivity equates to 
cross-protection. We also did not account for seasonality 
within this model, which may have under-estimated our FOI. 
Whitaker & Farrington41 found that accounting for seasonal-
ity resulting from past epidemics only had a marginal effect 
on the estimates, and that regular epidemic dynamics do not 
strongly bias the catalytic model. On the other hand, Ferrari 
et al.42 found that ignoring seasonality may overemphasize the 
role of adults in the transmission. We also assume an overall 
FOI by age, and we do not account for differences in popu-
lation susceptibility, for example health care workers or 
immunocompromised individuals. Despite these limitations, the 
duration of immunity estimated in this study is in line with 
literature estimates, suggesting the age-varying reverse catalytic 
model was able to capture overall dynamics.
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Numerous studies have looked at the age pattern of HCoV 
patients presenting to hospital and healthcare settings, and 
predominantly found that the burden of disease is higher in 
younger children and the elderly43–45. However, it is likely that 
these age groups may have more severe symptoms and are there-
fore more likely to be reported. In contrast, seroprevalence data 
makes it possible to examine the whole population for evi-
dence of past exposure, and hence can provide a clearer 
understanding of the underlying transmission dynamics of 
disease, rather than just the resulting burden.
In this study, when the relative change in FOI and the age of 
cut-off were simultaneously estimated across studies, we found 
that the FOI was estimated to be twice as high in the older age 
group (in this case, those over 8.49 [CrI: 7.52 - 9.94] years), 
compared with the younger age group. A similar pattern was 
observed for three of five datasets when the relative change 
in FOI and the cut-off age were allowed to vary by setting. 
This suggests that older children and adults may be important 
for the transmission of seasonal HCoVs in some settings. A 
previous study looking at social mixing patterns in Europe46 
found that children are expected to have the highest inci-
dence during the initial stages of an epidemic as a result of 
their social mixing patterns, and this is what is found for some 
diseases, such as seasonal influenza, where there is evidence 
young children drive transmission47,48. However, a more recent 
study looking at a large scale dataset of movement and contact 
patterns in the United Kingdom data found contact inten-
sity was highest in the 18–30 year age group when looking 
at all types of contacts (conversational, which was defined as 
face-to-face conversation of three or more words, and physi-
cal), although for physical alone, those aged 5–9 years had the 
highest contact49. Therefore, any association between contact 
intensity and transmission will depend on the contacts consid-
ered, particularly if a pathogen is more commonly spread via 
conversational contacts or via prolonged physical contacts. One 
possible explanation for the higher FOI we estimate in older 
age groups is that conversational contacts – which are typically 
higher in volume but lower in duration and intensity – could be 
more important for the transmission of seasonal HCoVs.
The results from this study are in accordance with what studies 
have observed in children during the coronavirus disease 2019 
(COVID-19) pandemic, with low numbers of cases reported 
in young age groups, and several large seroprevalence studies 
have reported lower seroprevalence in children compared with 
adults50,51. As well as differences in contact structure, this 
could be explained in part by reduced susceptibility to acquisi-
tion of infection, and a meta-analysis of contact tracing studies 
found that children had 56% (31% – 71%) lower odds of 
becoming an infected contact compared with adults52.
The duration of immunity to SARS-CoV-2 is still largely 
unknown and is of significance for the interpretation of population 
wide serological data, the understanding of the long-term 
dynamics of the epidemic, as well as of clinical importance. 
Given the long-term circulation of seasonal HCoVs, data on 
these related coronaviruses could provide indications of the 
possible future dynamics of SARS-CoV-2. With infection 
likely to become endemic in parts of the world, the duration of 
antibody-mediated immune responses will be particularly impor-
tant in shaping transmission patterns in years to come. Using 
seroprevalence data, in this study we estimated the duration 
of seropositivity to seasonal HCoVs following seroconver-
sion to be between 0.9 (95% CrI: 0.6 - 1.6) years and 3.8 (95% 
CrI: 2.0 - 7.4) years. We allowed the FOI to vary by age group 
and found it to be lower in young children (≤8.5 years) compared 
with older children and adults, which is corroborated with 
what has been observed in the COVID-19 pandemic. This 
suggests individuals in settings with endemic HCoVs accumulate 
multiple infections over the course of their lifetime, punctuated 
by periods of waning seropositivity against circulating viruses.
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Leveraging data on other human coronaviruses (HCoV) that have been circulating for longer, the 
authors estimated a range of antibody waning rates that might apply to SARS-CoV-2. They 
performed multiple sensitivity analyses to assess the robustness of their estimates. Their results 
also pointed towards transmission being higher in older individuals. 
 
The authors provided ample background to understand the motivation and the approach of their 
work. Below are some minor points that I view should be addressed. 
 
1) Please consider using the term ‘seropositivity waning rate’ instead of ‘immunity waning rate’ for 
ω as many of the assays in the dataset are binding assays which may not directly translate to 
protection, though correlated. 
 
2) I appreciate that the authors included multiple sensitivity analyses in their study. I would like to 
suggest one more where waning rates are assay specific. The assays measure different functional 
aspects of the antibodies which may involve different subsets of the induced repertoires. Some 
hints exist in the authors’ results. Shao (2007) and Chan (2009) used IgG ELISA while Monto (1974) 
and Sarateanu (1980) were HI based. Looking at plots of the observed data, these tend to exhibit 
more prominent wanes. In Table S6, Model 1, 5, and 6 where Monto (1974) and Sarateanu (1980) 
were included, the estimated waning rates were much higher than the others. It could be that 
these were specific to HCoV-OC43, but looking at Table S2, the estimates for -NL63 and -HKU1 
were similar to -OC43 (considering both the point estimates and credible intervals). Posterior 
density plots from code provided by the authors showed that combined cutoff of the Cavallaro 
(1970) and the Monto (1974) study in the main model, though converged, is bimodal. I wonder if 
this resulted from the model trying to accommodate the enforced single waning rate between 
studies which used different assays. This assessment will likely help the field reconcile 
discrepancies in serosurveys that were measured using different assays. 
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3) As the authors pointed out, data for some strains were from the same settings. This is evidence 
for co-circulation. The cross-reactivity between strains, specifically within alpha- and beta-CoVs, 
would affect the seropositivity. I acknowledge that literature is slim on what the degree of cross-
reactivity is and the limited data may make it hard to infer from the data. Anyhow, please consider 
adding some discussion around how this would change the estimated waning rate as it will help 
readers adjust their expectations on what the true waning rates could be. One way to gain such 
intuition may involve extending the models to include cross-reactivity in studies with known co-
circulation, imposing different sets of informative priors to the cross-reactivity rate, and assess 
how those affect the inferred waning rates. It is optional whether the authors would take on this 
path. 
 
4) The authors may consider additional metrics of model performance, for instance, the expected 
log predictive density (ELPD) which is based on approximate leave-one-out cross-validation, 
https://doi.org/10.1007/s11222-016-9696-4. The measure provides uncertainties around the 
performance estimates which may help determine the superiority among the suite of models, 
especially for ones where DIC were very similar. 
 
5) It would be helpful to provide an equation to explicitly show the link between the estimated 
waning rates and the duration of antibody persistence which were reported throughout the 
paper, and is the main finding of the study. 
 
6) In contrast to the previous point, the authors provided an equation linking the FOI to the attack 
rates but barely touched upon this topic in the paper except for one occurrence in the Discussion. 
May there be ideas that the authors wished to discuss but were not fully expressed in the text? 
 
7) It is unclear what the motivation for the analysis which led to Figure 3 was. Providing some 
context, especially how that would better our projections on SARS-CoV-2 would be helpful. 
 
8) Lastly, there are some truncated sentences or missing/inconsistent information in the paper 
that needs to be fixed. For example:
In the Methods, “The different assays used in each study for the different strains is shown, 
and where the antibody detected was specified this is included in the table.” 
 
○
In the Results, “When the relative change in FOI and cut-off parameters were 
simultaneously estimated by setting (extended data Figure 2, Table 3) the duration of 
antibody persistence was estimated to be shorter, …”. 
 
○
According to the captions, it occurs to me that the pairings are as follows: 
Table S1 with Figure S1, Table S3 with Figure S2, Table S5 with Figure S4. The pair of Table 
S2 is not obvious. It is unclear for Figure S3 which analysis this belongs to. Please also 
double check that the Extended data section in the main text matches the materials 
provided in the supplement.
○
“The inference was impleented in RJags…” 
 
○
The figure legend of Figure 3A says “reverse catalytic & age varying FOI” while the caption 
says “reverse catalytic model with time-varying FOI”. The colors also do not seem to match 
the legend (blue vs green vs grey). May be helpful to choose colors that are more different, 
○
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especially that the lines in the legend keys are quite thin. 
 
It is unclear which model was used to generate Figure 3B. I am guessing the “reverse 




Please consider breaking this portion in the Discussion into a new sentence, “... and a meta-
analysis of contact tracing studies found that children had 56% (31% – 71%) lower odds of 
becoming an infected contact compared with adults52.”
○
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